Svas Biosana SpAMIL:SVS 80 EBITDA Margin % is 13.36% as of Dec. 2025, which is 5% above its 10-year median of 12.67. GuruFocus rates MIL:SVS with a GF Score™ of 80/100 and a GF Value™ of €9.63 (Fairly Valued). The stock has 3 warning signs investors should review. Among 815 Medical Devices & Instruments companies, Svas Biosana SpA ranks better than 61.84% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Svas Biosana SpA's EBITDA for the
six
months ended in Dec. 2025 was €9.5 Mil. Svas Biosana SpA's Revenue for the
six
months ended in Dec. 2025 was €71.1 Mil. Therefore, Svas Biosana SpA's EBITDA margin for the quarter that ended in Dec. 2025 was 13.36%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Svas Biosana SpA EBITDA Margin % Related Terms
Svas Biosana SpA EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Svas Biosana SpA's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MIL:SVS vs ABT, SYK, MDT: EBITDA Margin % Comparison
For the Medical Devices subindustry, Svas Biosana SpA's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Svas Biosana SpA EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Svas Biosana SpA's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Svas Biosana SpA's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Svas Biosana SpA (MIL:SVS) has a EBITDA Margin % of 13.36% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Svas Biosana SpA and its competitors. This is near median its historical median of 12.67. Over the past decade, Svas Biosana SpA's EBITDA Margin % has ranged from 11.37 to 14.41. According to the industry distribution chart, Svas Biosana SpA ranks #311 out of 815 companies in the Medical Devices & Instruments industry, placing it in the top 38.2%.
Is Svas Biosana SpA's EBITDA Margin % too high?
Svas Biosana SpA's current EBITDA Margin % of 13.36% is near median its 10-year median of 12.67. Over the past 10 years, this metric has ranged from a low of 11.37 to a high of 14.41. The Medical Devices & Instruments industry median EBITDA Margin % is 7.47. Svas Biosana SpA's value of 13.36% is 78.8% above this industry median. Based on the distribution chart, Svas Biosana SpA ranks #311 out of 815 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Svas Biosana SpA has a GF Score™ of 80/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Svas Biosana SpA's EBITDA Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Svas Biosana SpA ranks #311 out of 815 companies for EBITDA Margin %. This puts Svas Biosana SpA in the upper half of its industry. The industry median EBITDA Margin % is 7.47. Svas Biosana SpA's value of 13.36% is 78.8% above this benchmark. Historically, Svas Biosana SpA's own EBITDA Margin % has ranged from 11.37 to 14.41 over the past decade. While the company's 10-year median is 12.67 vs. the industry median of 7.47, Svas Biosana SpA has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.47, based on 815 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Svas Biosana SpA's current EBITDA Margin % of 13.36% is 78.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Svas Biosana SpA and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Svas Biosana SpA's current EBITDA Margin % is 13.36%, which is near median its own 10-year median of 12.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Svas Biosana SpA stock overvalued right now?
Based on GuruFocus' analysis, Svas Biosana SpA (MIL:SVS) is currently considered Fairly Valued. The stock's GF Value™ is €9.63, compared to a current price of €9.24 — trading 4% below its estimated fair value. The current EBITDA Margin % is 13.36%, which is near median its 10-year median of 12.67 and 78.8% above the Medical Devices & Instruments industry median of 7.47. Svas Biosana SpA's overall GF Score™ is 80/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Svas Biosana SpA (MIL:SVS), the current EBITDA Margin % is 13.36% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Svas Biosana SpA (MIL:SVS) Overvalued in 2026?
Based on GuruFocus' analysis, Svas Biosana SpA stock appears to be undervalued.
The current stock price of €9.24 is trading 4% below its estimated GF Value™ of €9.63.
GuruFocus considers Svas Biosana SpA to be Fairly Valued.
Key valuation signals for MIL:SVS:
EBITDA Margin %: 13.36% (near median its 10-year median of 12.67)
GF Value™: €9.63 vs. price of €9.24 (4% below fair value)
Industry Position: 78.8% above the Medical Devices & Instruments median (#311 of 815)
No single metric tells the full story. See the MIL:SVS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MIL:SVS has been successfully added to your 
